04Recent Activity
Published its investment rationale for Metri Bio, a Yale spinout developing endometrial disease therapeutics after a $5M pre-seed.
MAR 26, 2026
Metri Bio is a biotechnology company focused on developing first-in-class therapeutics for endometrial diseases, particularly endometriosis, using advanced 3D endometrial modeling technology
Metri Bio is a biotechnology company focused on developing first-in-class therapeutics for endometrial diseases, particularly endometriosis, using advanced 3D endometrial modeling technology.